ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Hospital launches a gene therapy subsidiary

by Rick Mullin
January 16, 2020 | APPEARED IN VOLUME 98, ISSUE 3

Nationwide Children’s Hospital, a research hospital specializing in gene therapy, has launched a for-profit biotechnology subsidiary called Andelyn Biosciences. Scheduled to begin commercial-scale production at a new facility in 2023, Andelyn will manufacture gene therapy products for the pharmaceutical industry. Nationwide already offers production for clinical trials and says commercial capacity is needed as more gene therapies are developed in the coming years.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment